Clinical trials: Liver Cell Carcinoma Non-resectable
Hepatocellular Carcinoma
Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma
The purpose of this study is to develop better ways to treat liver cancer, known as hepatocellular carcinoma or HCC, while it is still in the liver.
- Trial name
- NCT02513199
- Testing
- SBRT, TACE
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatocellular Carcinoma
HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC
MDS Nordion's TheraSphere, Yttrium-90 glass microspheres has been approved as a Humanitarian device authorized by federal(USA)law for use in radiation treatment or as a neoadjuvant to surgery or transplantation in patients with…
- Trial name
- NCT00605150
- Testing
- TheraSphere-Yttrium 90 microsphere
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Hepatocellular Carcinoma Non-resectable
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
This study is conducted to evaluate the efficacy and safety of transarterial chemoembolization with drug-eluting beads (DEB-TACE) combined with hepatic artery infusion chemotherapy (HAIC) with oxaliplatin and raltitrexed…
- Trial name
- NCT06397235
- Testing
- DEB-TACE+HAIC, DEB-TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Unresectable Hepatocellular Carcinoma
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with…
- Trial name
- IMbrave251 (NCT04770896)
- Testing
- Atezolizumab, Lenvatinib, Sorafenib
- Where
- 124 sites in Austria, Belgium and 26 more
- Volunteers
- 557 people
- Sponsor
- Hoffmann-La Roche
Hepatocellular Carcinoma
HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) compared with transarterial chemoembolization (TACE) in patients with large and unresectable hepatocellular…
- Trial name
- NCT03048123
- Testing
- Hepatic arterial infusion, Transarterial chemoembolization, Folfox Protocol
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma
This is a phase II, open-label study to evaluate the efficacy and safety of Durvalumab plus Lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma.
- Trial name
- NCT05312216
- Testing
- Durvalumab plus Lenvatinib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Zhejiang University
Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
This randomized phase III trial studies sorafenib tosylate and doxorubicin hydrochloride to see how well they work compared with sorafenib tosylate alone in treating patients with liver cancer that has spread to nearby tissue or…
- Conditions
- Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7
- Trial name
- NCT01015833
- Testing
- Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study
- Where
- 673 sites in United States, Canada and 1 more
- Volunteers
- 356 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Hepatocellular
Individualized Dosimetry for Holmium-166 Radioembolization in Patients With Unresectable Hepatocellular Carcinoma
The goal of this clinical trial is to test the safety and effectiveness of a medical device called 166-Holmium microspheres (QuiremSpheres®) in patients with hepatocellular carcinoma (HCC) .
- Trial name
- RHEPaiR (NCT06302400)
- Testing
- 166Holmium microspheres (QuiremSpheres®)
- Where
- United Kingdom
- Volunteers
- 4 people
- Sponsor
- Imperial College London
Glioma, Hematopoietic and Lymphoid Cell Neoplasm
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction.
- Conditions
- Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma, Metastatic Malignant Solid Neoplasm
- Trial name
- NCT01638533
- Testing
- Pharmacological Study, Romidepsin
- Where
- 12 sites in United States, Canada
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma Non-resectable
Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC
This study is conducted to evaluate the efficacy and safety of regorafenib plus sintilimab compared with regorafenib alone as the second-line treatment for patients with unresectable hepatocellullar carcinoma (HCC).
- Trial name
- REGSIN (NCT04718909)
- Testing
- Regorafenib + sintilimab, Regorafenib
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma (HCC)
Liver Volume Metrics for Predicting Immunotherapy Prognosis in Unresectable Hepatocellular Carcinoma
This multicenter retrospective cohort study aims to evaluate the prognostic value of functional liver volume and total liver volume in patients with unresectable hepatocellular carcinoma (HCC) undergoing immunotherapy.
- Trial name
- NCT07782632
- Testing
- Baseline Liver Volume Volumetric Analysis
- Where
- China
- Volunteers
- 467 people
- Sponsor
- Anhui Provincial Hospital
Hepatocellular Carcinoma
Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC
To investigate efficacy and toxicity of regorafenib after treatment with atezolizumab and bevacizumab combination
- Trial name
- HCC (NCT05134532)
- Testing
- regorafenib
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- CHA University
Hepatocellular Carcinoma
Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma
- Trial name
- NCT07157306
- Testing
- Gecacitinib Combined With Donafenib and PD-1 Inhibitor
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Liver Cancer
Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer
This is a clinical trial to test the safety and efficacy of the drug thalidomide in combination with a procedure called chemoembolization in patients with inoperable liver cancer.
- Trial name
- NCT00006198
- Testing
- thalidomide, chemoembolization with doxorubicin/collagen
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Carcinoma, Hepatocellular, Hepatocellular Cancer
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that…
- Conditions
- Carcinoma, Hepatocellular, Hepatocellular Cancer, Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT07227012
- Testing
- PF-08634404, Ipilimumab
- Where
- 60 sites in United States, China and 3 more
- Volunteers
- 138 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma
TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma
It is an exploratory clinical study aimed to evaluate the efficacy and safety of TACE combined with Lenvatinib in the treatment of patients with BCLC stage B and C HCC.Treatment will continue until the death or intolerable…
- Trial name
- NCT04490694
- Testing
- Lenvatinib, TACE
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai Zhongshan Hospital
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Hepatocellular Carcinoma
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick," to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Trial name
- NCT00054951
- Testing
- MTC-DOX for Injection
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- FeRx
Hepatocellular Carcinoma Non-resectable
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT05608200
- Testing
- Lenvatinib, sintilimab plus TACE, Lenvatinib plus TACE
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma
Randomized Control Trial (RCT) of Transarterial Chemoembolization (TACE) Versus TACE and Oral Drug Therapy in the Treatment of Unresectable Hepatocellular Carcinoma
Background Hepatocellular carcinoma, a malignant tumor of liver is one of the most common cancers worldwide. All India Institute Of Medical Sciences (AIIMS) being a tertiary care hospital receives about two to three cases of…
- Trial name
- NCT00522405
- Testing
- TACE
- Where
- India
- Sponsor
- All India Institute of Medical Sciences